Pathogenesis of Respiratory Syncytial Virus Infection in the Murine Model

Overview

Journal Proc Am Thorac Soc

Specialty Pulmonary Medicine

Date 2005 Aug 23

PMID 16113477

Citations 58

Authors

R Stokes Peebles Jr

Barney S Graham

Affiliations

Soon will be listed here.

Abstract

There is a wide spectrum of illness caused by respiratory syncytial virus (RSV) infection that is caused in large part by host-related factors, such as age of the patient and degree of host immunocompetency. Although the vast majority of persons infected with RSV experience symptoms of mild upper respiratory tract infection, in some people these infections cause significant morbidity and are sometimes fatal. Although a great deal of investigation in both humans and animals has explained the timing and tropism of RSV infection and the general principles by which the immune system responds to this infection, at present we only partially understand the disparity in illness severity that can occur. This article briefly reviews the clinical sequelae of RSV infection and then focuses on the mechanisms of viral pathogenesis.

Citing Articles

A complex remodeling of cellular homeostasis distinguishes RSV/SARS-CoV-2 co-infected A549-hACE2 expressing cell lines.

Vanetti C, Saulle I, Artusa V, Moscheni C, Cappelletti G, Zecchini S Microb Cell. 2024; 11:353-367.

PMID: 39421150 PMC: 11486504. DOI: 10.15698/mic2024.10.838.

IRF3 inhibits inflammatory signaling pathways in macrophages to prevent viral pathogenesis.

Chakravarty S, Varghese M, Fan S, Taylor R, Chakravarti R, Chattopadhyay S Sci Adv. 2024; 10(32):eadn2858.

PMID: 39121222 PMC: 11313863. DOI: 10.1126/sciadv.adn2858.

Hypoxia inducible factors inhibit respiratory syncytial virus infection by modulation of nucleolin expression.

Zhuang X, Gallo G, Sharma P, Ha J, Magri A, Borrmann H iScience. 2024; 27(1):108763.

PMID: 38261926 PMC: 10797196. DOI: 10.1016/j.isci.2023.108763.

Development of an Antiviral Ion-Activated In Situ Gel Containing 18β-Glycyrrhetinic Acid: A Promising Alternative against Respiratory Syncytial Virus.

Ozkan B, Altuntas E, Unlu U, Dogan H, Ozsoy Y, Cakir Koc R Pharmaceutics. 2023; 15(8).

PMID: 37631269 PMC: 10458153. DOI: 10.3390/pharmaceutics15082055.

SARS-CoV-2: A Master of Immune Evasion.

Rubio-Casillas A, Redwan E, Uversky V Biomedicines. 2022; 10(6).

PMID: 35740361 PMC: 9220273. DOI: 10.3390/biomedicines10061339.

References

Johnson T, Parker R, Johnson J, Graham B . IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol. 2003; 170(4):2037-45. DOI: 10.4049/jimmunol.170.4.2037. View

Tekkanat K, Maassab H, Miller A, Berlin A, Kunkel S, Lukacs N . RANTES (CCL5) production during primary respiratory syncytial virus infection exacerbates airway disease. Eur J Immunol. 2003; 32(11):3276-84. DOI: 10.1002/1521-4141(200211)32:11<3276::AID-IMMU3276>3.0.CO;2-5. View

Ellis S, Coffey C, Mitchel Jr E, Dittus R, Griffin M . Influenza- and respiratory syncytial virus-associated morbidity and mortality in the nursing home population. J Am Geriatr Soc. 2003; 51(6):761-7. PMC: 7159134. DOI: 10.1046/j.1365-2389.2003.51254.x. View

John A, Berlin A, Lukacs N . Respiratory syncytial virus-induced CCL5/RANTES contributes to exacerbation of allergic airway inflammation. Eur J Immunol. 2003; 33(6):1677-85. DOI: 10.1002/eji.200323930. View

Abdallah A, Rowland K, Schepetiuk S, To L, Bardy P . An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect on engraftment and outcome of pneumonia without specific antiviral treatment. Bone Marrow Transplant. 2003; 32(2):195-203. DOI: 10.1038/sj.bmt.1704116. View

Wainwright C, Altamirano L, Cheney M, Cheney J, Barber S, Price D . A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis. N Engl J Med. 2003; 349(1):27-35. DOI: 10.1056/NEJMoa022226. View

Makela M, Tripp R, Dakhama A, Park J, Ikemura T, Joetham A . Prior airway exposure to allergen increases virus-induced airway hyperresponsiveness. J Allergy Clin Immunol. 2003; 112(5):861-9. DOI: 10.1016/s0091-6749(03)02020-7. View

Davis I, Sullender W, Hickman-Davis J, Lindsey J, Matalon S . Nucleotide-mediated inhibition of alveolar fluid clearance in BALB/c mice after respiratory syncytial virus infection. Am J Physiol Lung Cell Mol Physiol. 2003; 286(1):L112-20. DOI: 10.1152/ajplung.00218.2003. View

Monick M, Yarovinsky T, Powers L, Butler N, Carter A, Gudmundsson G . Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem. 2003; 278(52):53035-44. DOI: 10.1074/jbc.M308093200. View

10.

Nielsen H, Siersma V, Andersen S, Gahrn-Hansen B, Mordhorst C, Norgaard-Pedersen B . Respiratory syncytial virus infection--risk factors for hospital admission: a case-control study. Acta Paediatr. 2003; 92(11):1314-21. View

11.

Mellow T, Murphy P, Carson J, Noah T, Zhang L, Pickles R . The effect of respiratory synctial virus on chemokine release by differentiated airway epithelium. Exp Lung Res. 2004; 30(1):43-57. DOI: 10.1080/01902140490252812. View

12.

Spann K, Tran K, Chi B, Rabin R, Collins P . Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J Virol. 2004; 78(8):4363-9. PMC: 374276. DOI: 10.1128/jvi.78.8.4363-4369.2004. View

13.

Miller A, Bowlin T, Lukacs N . Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo. J Infect Dis. 2004; 189(8):1419-30. DOI: 10.1086/382958. View

14.

Garofalo R, Hintz K, Hill V, Ogra P, Welliver Sr R . Production of interferon gamma in respiratory syncytial virus infection of humans is not associated with interleukins 12 and 18. J Med Virol. 2004; 73(2):289-94. DOI: 10.1002/jmv.20089. View

15.

Khalifah A, Hachem R, Chakinala M, Schechtman K, Patterson G, Schuster D . Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004; 170(2):181-7. DOI: 10.1164/rccm.200310-1359OC. View

16.

Hashimoto K, Graham B, Ho S, Adler K, Collins R, Olson S . Respiratory syncytial virus in allergic lung inflammation increases Muc5ac and gob-5. Am J Respir Crit Care Med. 2004; 170(3):306-12. DOI: 10.1164/rccm.200301-030OC. View

17.

Johnson T, Varga S, Braciale T, Graham B . Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J Virol. 2004; 78(16):8753-60. PMC: 479099. DOI: 10.1128/JVI.78.16.8753-8760.2004. View

18.

Heymann P, Carper H, Murphy D, Platts-Mills T, Patrie J, McLaughlin A . Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing. J Allergy Clin Immunol. 2004; 114(2):239-47. PMC: 7185400. DOI: 10.1016/j.jaci.2004.04.006. View

19.

Rutigliano J, Graham B . Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection. J Immunol. 2004; 173(5):3408-17. DOI: 10.4049/jimmunol.173.5.3408. View

20.

Law B, Langley J, Allen U, Paes B, Lee D, Mitchell I . The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004; 23(9):806-14. DOI: 10.1097/01.inf.0000137568.71589.bd. View